J Liver Cancer.  2024 Mar;24(1):7-8. 10.17998/jlc.2023.10.08.

Performance of HCC diagnosis in the KLCA-NCC guidelines: a closer look at MRI contrast agents and HCC imaging hallmarks

• Min JH
• Kim YK

• KMID: 2553812
• DOI: http://doi.org/10.17998/jlc.2023.10.08

Reference

References

1. Yoon JK, Lee S, Hwang JA, Lee JE, Kim SS, Kim MJ. Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria. J Liver Cancer. 2023; 23:157–165.

2. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Korean J Radiol. 2022; 23:1126–1240.

3. Vogl TJ, Kümmel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors: comparison of MR imaging with Gd-EOBDTPA and Gd-DTPA. Radiology. 1996; 200:59–67.

4. Paisant A, Vilgrain V, Riou J, Oberti F, Sutter O, Laurent V, et al. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol. 2020; 72:937–945.

5. Min JH, Kim JM, Kim YK, Kang TW, Lee SJ, Choi GS, et al. Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system. Hepatology. 2018; 68:2254–2266.

6. Yoon JH. Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018. J Liver Cancer. 2023; 23:124–126.